RheumaGen is a pre-clinical cell and gene therapy company editing the HLA gene to develop cures for rheumatoid arthritis and other autoimmune diseases.
Total raised: $15M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.01.2025 | Series A | $15M | - |
Mentions in press and media 4
| Date | Title | Description |
| 13.01.2025 | RheumaGen's $15 Million Leap: A New Dawn for Autoimmune Treatment | RheumaGen, a beacon of hope in the world of autoimmune disease treatment, has successfully raised $15 million in Series A funding. This Aurora, Colorado-based company is not just another player in the biotech arena; it’s a pioneer aiming to... |
| 11.01.2025 | RheumaGen: Gene Therapy Company Raises $15 Million (Series A) | RheumaGen – a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases – announced the closing of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. Th... |
| 10.01.2025 | RheumaGen Raises $15M in Series A Funding | RheumaGen, an Aurora, CO-based cell and gene therapy company, raised $15M in Series A funding. The round was led by SPRIM Global Investments and William Taylor Nominees. The company intends to use the funds to support the Phase I clinical t... |
| - | RheumaGen | “RheumaGen” |